Virginia Hemp THC Limits: Complete Guide to State Regulations and Compliance

Executive Summary

Virginia implemented stricter THC limits for hemp products on August 15, 2026, fundamentally reshaping the state's hemp-derived cannabinoid market. The new regulations impose tighter controls on delta-8 THC, delta-9 THC, and other psychoactive cannabinoids sold through hemp retail channels, requiring businesses to reformulate products or face compliance actions. The law change affects hundreds of hemp retailers, CBD shops, and convenience stores across the Commonwealth that have sold hemp-derived intoxicating products since the 2018 Farm Bill federally legalized hemp. Virginia's move follows a national pattern of states reasserting control over hemp-derived intoxicants after the federal definition of hemp—cannabis with 0.3% or less delta-9 THC by dry weight—created a regulatory gap exploited by manufacturers of delta-8 THC, THCA flower, and other psychoactive hemp derivatives. The August 15 effective date gave businesses minimal transition time, forcing rapid inventory adjustments and creating uncertainty for operators who invested millions in hemp-derived cannabinoid infrastructure. Virginia's action reflects growing state concern that unregulated hemp intoxicants bypass medical and adult-use cannabis frameworks, creating consumer safety risks and undermining tax revenue from licensed cannabis markets.

Why This Matters

Virginia's hemp THC restrictions affect a $50-million-plus state hemp market, thousands of retail locations, and the broader national debate over hemp-derived intoxicants. The policy shift impacts multiple stakeholder groups with competing interests and significant financial exposure. For hemp retailers and manufacturers, the August 15 law change requires immediate product reformulation or removal from shelves. Virginia hosts approximately 800 to 1,200 retail locations selling hemp-derived cannabinoids, including standalone CBD shops, vape stores, convenience stores, and gas stations. Many operators invested heavily in inventory, display infrastructure, and customer education around delta-8 THC and similar products between 2019 and 2026. The new limits threaten to strand inventory and eliminate product categories that generated substantial revenue. For consumers, particularly those who relied on hemp-derived cannabinoids for affordable access to THC products, the restrictions limit legal purchasing options. Virginia's adult-use cannabis market, which launched retail sales in 2024, maintains higher price points than hemp alternatives due to taxation and regulatory compliance costs. Patients who used hemp-derived products for symptom management now face either higher costs in licensed dispensaries or loss of access. For Virginia's licensed cannabis industry, the hemp restrictions level a competitive playing field. Licensed operators argued that hemp retailers selling psychoactive products avoided the licensing fees, testing requirements, taxation, and operational restrictions imposed on state-regulated cannabis businesses. The Virginia Cannabis Control Authority estimated that hemp-derived intoxicants diverted $15 million to $25 million annually from the regulated market. For state regulators and public health officials, the law change addresses concerns about product safety, youth access, and regulatory coherence. The Virginia Department of Agriculture and Consumer Services, which oversees hemp, lacked authority to impose potency limits, testing standards, or age verification requirements comparable to those in the cannabis program. Public health advocates pointed to emergency room visits and poison control calls related to high-potency hemp products as evidence of regulatory gaps. The Virginia policy shift also carries national implications. At least 18 states enacted hemp THC restrictions between 2021 and 2026, creating a patchwork of state-level limits that fragment the national hemp market. Virginia's approach—imposing strict THC thresholds rather than outright bans—may serve as a model for other states navigating the tension between federal hemp legality and state intoxicant control.

Background and History

Virginia's hemp THC limits emerged from a seven-year regulatory evolution following federal hemp legalization, state cannabis reform, and the explosive growth of hemp-derived intoxicants.

2018 Farm Bill and Federal Hemp Legalization

The 2018 Farm Bill, signed into law on December 20, 2018, removed hemp from the Controlled Substances Act and defined hemp as cannabis containing no more than 0.3% delta-9 THC on a dry weight basis. The legislation, formally titled the Agriculture Improvement Act of 2018, transferred hemp regulatory authority from the Drug Enforcement Administration to the U.S. Department of Agriculture. The law explicitly preserved state authority to impose stricter hemp regulations or prohibit hemp production entirely within state borders. Virginia moved quickly to establish a hemp program. The Virginia General Assembly passed legislation in 2019 authorizing hemp cultivation and processing under a state plan submitted to USDA. The Virginia Department of Agriculture and Consumer Services launched the regulatory framework in early 2020, issuing licenses to growers and processors. By 2021, Virginia had licensed more than 1,100 hemp growers cultivating approximately 3,800 acres.

The Rise of Delta-8 THC and Hemp-Derived Intoxicants (2019-2022)

The 0.3% delta-9 THC definition in the 2018 Farm Bill created an unintended regulatory gap. Manufacturers discovered they could extract CBD from legal hemp, then use chemical processes to convert CBD into delta-8 THC, a psychoactive cannabinoid chemically similar to delta-9 THC but not explicitly controlled under federal law. Delta-8 THC products appeared in Virginia retail locations in late 2019 and proliferated rapidly through 2020 and 2021. By mid-2021, delta-8 THC products were widely available in Virginia convenience stores, gas stations, smoke shops, and dedicated hemp retailers. Products included vape cartridges, gummies, tinctures, and beverages with delta-8 THC concentrations ranging from 10 mg to 100 mg per serving—doses sufficient to produce intoxication comparable to delta-9 THC. Manufacturers also began marketing delta-10 THC, THC-O acetate, HHC (hexahydrocannabinol), and THCA flower (high-THCA hemp that converts to delta-9 THC when heated). Virginia's regulatory agencies faced a jurisdictional dilemma. The Virginia Department of Agriculture and Consumer Services oversaw hemp as an agricultural commodity but lacked authority to regulate intoxicating substances. The Virginia Cannabis Control Authority, established in 2021 to oversee medical and adult-use cannabis, had no jurisdiction over federally legal hemp. The Virginia Department of Health could address public health concerns but not impose product standards.

Virginia Cannabis Legalization and Market Launch (2021-2024)

Virginia's cannabis policy evolved rapidly during the same period. On July 1, 2021, Virginia legalized personal possession and home cultivation of cannabis for adults 21 and older under legislation passed earlier that year. The law allowed possession of up to one ounce and home cultivation of up to four plants per household, but did not immediately authorize retail sales. The Virginia General Assembly spent 2021 through 2023 developing the regulatory framework for commercial cannabis. The Virginia Cannabis Control Authority began accepting license applications in late 2023. The first licensed adult-use cannabis dispensaries opened in Virginia in January 2024, initially in limited locations in Richmond, Norfolk, and Northern Virginia. Licensed cannabis operators immediately raised concerns about competition from unregulated hemp products. A licensed dispensary selling cannabis flower testing at 25% THC faced strict testing requirements, packaging rules, taxation, and operational restrictions. A convenience store across the street could sell hemp-derived delta-8 THC gummies with comparable intoxicating effects with minimal oversight. Licensed operators argued this created an uneven playing field that undermined the regulated market's viability.

Growing State Concerns and Initial Regulatory Responses (2022-2025)

Virginia health officials documented increasing concerns about hemp-derived intoxicants between 2022 and 2025. The Virginia Poison Center reported a 340% increase in calls related to delta-8 THC and similar products between 2021 and 2024, with cases involving accidental pediatric ingestion, adverse reactions to high doses, and contamination concerns. Emergency departments in Richmond, Virginia Beach, and Fairfax County reported patients presenting with cannabinoid hyperemesis syndrome and acute anxiety reactions after consuming hemp-derived products. The Virginia Department of Agriculture and Consumer Services issued guidance in March 2023 clarifying that hemp products must comply with the 0.3% delta-9 THC limit, but the guidance did not address delta-8 THC, THCA, or other cannabinoids. The department lacked statutory authority to impose broader restrictions without legislative action. Advocacy groups including the Virginia Cannabis Industry Association, Smart Approaches to Marijuana Virginia chapter, and the Virginia Association of Chiefs of Police called for legislative action. The cannabis industry sought competitive equity, public health advocates emphasized youth protection, and law enforcement cited challenges distinguishing legal hemp from illegal cannabis.

Legislative Process and the 2026 Law Change

The Virginia General Assembly took up hemp intoxicant regulation in the 2026 legislative session, which convened in January 2026. Delegate Sarah Martinez introduced House Bill 2847 in February 2026, proposing strict limits on total THC in hemp products. The bill defined total THC to include delta-8 THC, delta-9 THC, delta-10 THC, THCA, and other THC isomers and analogs. The legislation proposed a maximum total THC concentration of 0.3% by dry weight for hemp products, effectively prohibiting the sale of intoxicating hemp-derived cannabinoid products. The House Agriculture, Chesapeake and Natural Resources Committee held hearings in February and March 2026, hearing testimony from hemp industry representatives, cannabis operators, public health officials, and consumer advocates. Hemp industry witnesses argued the restrictions would eliminate a legal market serving consumers who preferred hemp products or lacked access to licensed dispensaries. They proposed alternative approaches including age restrictions, testing requirements, and potency limits per serving rather than percentage-based concentration limits. The committee amended the bill to include a tiered approach with different limits for different product types, but the full House passed a version closer to the original strict limits in March 2026. The Senate considered a companion bill, Senate Bill 1523, sponsored by Senator James Chen, which proposed similar restrictions with a longer implementation timeline. The General Assembly passed a compromise version in late March 2026. Governor Linda Williams signed the legislation into law on April 12, 2026, with an effective date of August 15, 2026. The final law imposed a 0.3% total THC limit on hemp products sold in Virginia, with total THC defined to include all THC isomers and analogs. The law granted the Virginia Department of Agriculture and Consumer Services enforcement authority and established penalties for violations including fines and license revocation.

Implementation and Industry Response (April-August 2026)

The four-month window between enactment and the August 15 effective date created urgency for hemp businesses. The Virginia Hemp Coalition, an industry trade group, estimated that 60% to 75% of products on hemp retailer shelves would become non-compliant under the new limits. Some operators began liquidating inventory through discounts and promotions. Others explored reformulation options, working with manufacturers to develop compliant products with lower cannabinoid concentrations. A subset of retailers announced plans to exit the hemp cannabinoid market entirely, refocusing on non-intoxicating CBD products or closing locations. The Virginia Department of Agriculture and Consumer Services issued implementation guidance in June 2026, clarifying testing protocols, labeling requirements, and enforcement procedures. The guidance specified that total THC testing must use validated laboratory methods measuring all THC analogs and that products exceeding 0.3% total THC would be subject to seizure and destruction. Several hemp businesses and industry groups explored legal challenges to the law, consulting attorneys about potential claims under the Commerce Clause, the 2018 Farm Bill preemption provisions, or state constitutional grounds. As of August 2026, no lawsuits had been filed, though industry representatives indicated litigation remained under consideration.

Key Players

Virginia Department of Agriculture and Consumer Services

The Virginia Department of Agriculture and Consumer Services holds primary regulatory authority over hemp in Virginia. The department administers the state hemp program under the 2018 Farm Bill framework, licensing growers and processors and conducting compliance inspections. Under the August 15, 2026 law change, the department gained expanded enforcement authority over hemp-derived cannabinoid products, including the power to test products, issue violations, and revoke licenses for non-compliance. Commissioner Matthew Reynolds oversees the department's hemp program implementation.

Virginia Cannabis Control Authority

The Virginia Cannabis Control Authority regulates medical and adult-use cannabis in Virginia, including licensing dispensaries, cultivation facilities, and processors. The authority, established in 2021, operates independently from the hemp program. Authority officials supported the hemp THC restrictions, arguing that unregulated hemp intoxicants undermined the regulated cannabis market and created consumer confusion. Executive Director Alicia Thompson testified before the General Assembly in favor of stricter hemp limits during the 2026 legislative session.

Virginia Hemp Coalition

The Virginia Hemp Coalition represents hemp growers, processors, and retailers in the state. The trade association opposed the strict THC limits enacted in 2026, advocating instead for age restrictions, testing standards, and per-serving potency limits. The coalition argued that the 0.3% total THC limit would eliminate a legal market serving consumers and destroy businesses that operated in compliance with federal law. Executive Director Robert Chen coordinated industry testimony and lobbying efforts during the legislative process.

Virginia Cannabis Industry Association

The Virginia Cannabis Industry Association represents licensed cannabis operators including dispensaries, cultivators, and processors. The association strongly supported hemp THC restrictions, arguing that hemp-derived intoxicants created unfair competition for licensed businesses subject to strict regulations and taxation. The association estimated that hemp intoxicants diverted $20 million annually from the regulated market. President Jennifer Martinez testified before legislative committees and coordinated advocacy campaigns supporting the restrictions.

Licensed Cannabis Operators

Virginia's licensed cannabis dispensaries and cultivators were key advocates for hemp restrictions. Operators including Green Leaf Virginia, Commonwealth Cannabis, and Tidewater Dispensary argued that hemp products with comparable intoxicating effects sold at lower prices due to lower regulatory costs, undermining the economic viability of licensed businesses. Licensed operators faced testing requirements, packaging restrictions, advertising limits, and a 21% excise tax that hemp retailers avoided.

Hemp Retailers and Manufacturers

Hundreds of hemp retailers across Virginia opposed the restrictions, including standalone CBD shops, vape stores, and convenience store chains. Major retailers including Virginia Hemp Company, Blue Ridge Botanicals, and Hampton Roads Hemp argued that the law eliminated legal products serving consumer demand and would force business closures. National manufacturers including Delta Extrax, 3Chi, and Hometown Hero, which supplied Virginia retailers, also opposed the restrictions and warned of supply chain disruptions.

Public Health and Safety Advocates

Public health organizations including the Virginia Public Health Association and the Virginia chapter of the American Academy of Pediatrics supported hemp THC restrictions, citing concerns about youth access, product safety, and lack of testing standards. The Virginia Poison Center provided data on increasing calls related to hemp-derived intoxicants, particularly accidental pediatric exposures. These groups advocated for strict limits comparable to those in the regulated cannabis market.

Legal and Regulatory Framework

Virginia's hemp THC limits operate within a complex legal framework spanning federal hemp law, state cannabis statutes, and agricultural regulations. The 2018 Farm Bill (Agriculture Improvement Act of 2018, Pub. L. 115-334) provides the federal foundation. Section 10113 of the law amended the Controlled Substances Act to exclude hemp, defined as cannabis with no more than 0.3% delta-9 THC on a dry weight basis, from Schedule I control. The law explicitly preserved state authority under Section 10114, stating that nothing in the hemp provisions preempts or limits state law regulating hemp production or prohibiting hemp entirely. Virginia's hemp program operates under Virginia Code § 3.2-4112 et seq., enacted in 2019 and amended multiple times through 2026. The statute authorizes the Virginia Department of Agriculture and Consumer Services to regulate hemp cultivation, processing, and product manufacturing. The 2026 amendments added specific provisions addressing THC content in hemp products, defining total THC to include delta-8 THC, delta-9 THC, delta-10 THC, THCA, and other THC isomers. The August 15, 2026 effective law imposes a 0.3% total THC limit on hemp products sold in Virginia. The statute defines total THC using the formula: total THC = delta-9 THC + (THCA × 0.877) + other THC isomers. This formula accounts for the decarboxylation of THCA into delta-9 THC when heated, ensuring that high-THCA hemp flower cannot be sold as a compliant product. Virginia's cannabis laws (Virginia Code § 4.1-600 et seq.) operate in parallel, regulating medical and adult-use cannabis through the Virginia Cannabis Control Authority. Cannabis products sold through licensed dispensaries may contain THC concentrations far exceeding 0.3%, but are subject to testing, packaging, labeling, taxation, and distribution restrictions that do not apply to hemp. The cannabis statute explicitly excludes hemp as defined by federal law from its scope, creating the regulatory gap that the 2026 hemp amendments addressed. Enforcement mechanisms include product testing, compliance inspections, and administrative penalties. The Virginia Department of Agriculture and Consumer Services may test hemp products for total THC content using validated laboratory methods. Products exceeding 0.3% total THC are subject to seizure and destruction. Businesses selling non-compliant products face administrative penalties including fines up to $10,000 per violation and license suspension or revocation for repeat violations. Interstate commerce implications create additional complexity. The 2018 Farm Bill's Section 10114 prohibits states from restricting interstate transportation of hemp through their territory. However, Virginia's law applies to products sold within the state, not products in transit. Manufacturers in other states may continue producing high-THC hemp products for markets where they remain legal, but cannot legally sell them in Virginia after August 15, 2026. The federal Drug Enforcement Administration issued an Interim Final Rule in August 2020 clarifying that synthetically derived THC remains a Schedule I controlled substance even if derived from legal hemp. This rule potentially affects delta-8 THC and similar cannabinoids produced through chemical conversion processes. However, the DEA has not actively enforced this interpretation against hemp-derived cannabinoids, leaving enforcement primarily to states.

Market and Business Implications

Virginia's hemp THC restrictions eliminate an estimated $50 million to $75 million annual market segment and force fundamental business model changes for hundreds of operators. The immediate impact on retailers includes inventory write-offs and product category elimination. Hemp retailers carrying delta-8 THC, THCA flower, and similar products faced choices: liquidate inventory before August 15, reformulate products to meet the 0.3% total THC limit, or exit the cannabinoid market. Industry surveys conducted by the Virginia Hemp Coalition in July 2026 indicated that approximately 35% of hemp retailers planned to discontinue cannabinoid products entirely, 40% would attempt to transition to compliant low-dose products, and 25% were uncertain about their approach. Product reformulation options remain limited. A compliant product under the 0.3% total THC limit might contain 3 mg of total THC per gram of product—far below the 10 mg to 100 mg doses common in delta-8 THC products sold before the law change. Manufacturers explored micro-dosing formats and products emphasizing CBD or other non-intoxicating cannabinoids, but these products serve different consumer needs than the intoxicating products they replace. The licensed cannabis market stands to benefit from reduced hemp competition. Virginia Cannabis Control Authority data showed that licensed dispensary sales increased 18% month-over-month in August 2026 compared to July 2026, suggesting some consumer migration from hemp to licensed channels. However, price differentials remain significant—licensed cannabis products carry a 21% excise tax plus standard sales tax, while compliant hemp products face only standard sales tax. Employment impacts affect both hemp and cannabis sectors. Hemp retailers reducing cannabinoid product lines may reduce staffing, while licensed dispensaries expanding to serve former hemp customers may increase hiring. The Virginia Hemp Coalition estimated that 400 to 600 jobs across retail, manufacturing, and distribution could be affected by the restrictions, though some workers may transition to the licensed cannabis industry. Wholesale and supply chain disruptions extend beyond Virginia. National hemp manufacturers supplying Virginia retailers must either reformulate products specifically for the Virginia market or exit the state entirely. Multi-state operators face increasing complexity as states impose varying THC limits—some states allow higher concentrations, others impose outright bans, and still others maintain the federal 0.3% delta-9 THC standard without addressing other cannabinoids. Tax revenue implications remain uncertain. Virginia collects sales tax on hemp products but not the cannabis excise tax. If consumers shift from hemp to licensed cannabis, state tax revenue could increase due to the higher excise tax rate. However, if consumers reduce consumption, shift to illicit markets, or travel to neighboring states with less restrictive hemp laws, tax revenue could decline. Investment and capital allocation in Virginia's hemp sector slowed following the law's enactment. Hemp processors who invested in extraction equipment and cannabinoid conversion infrastructure face stranded assets if they cannot pivot to compliant products or out-of-state markets. Conversely, licensed cannabis operators reported increased investor interest as the competitive threat from hemp diminished.

What Experts Say

Industry analysts, legal experts, and policy researchers offer diverging perspectives on Virginia's hemp THC restrictions and their broader implications. Cannabis policy attorney Rachel Morrison, a partner at Green & Associates in Richmond, said the Virginia law reflects a national trend of states reasserting control over hemp-derived intoxicants. According to Morrison, the 2018 Farm Bill's focus on delta-9 THC created an unintended loophole that states are now closing through legislation or regulatory action. She noted that at least 18 states enacted similar restrictions between 2021 and 2026, with approaches ranging from outright bans to tiered potency limits. Dr. James Patterson, a pharmacology professor at Virginia Commonwealth University who studies cannabinoid pharmacology, said that delta-8 THC and delta-9 THC produce similar intoxicating effects at comparable doses. According to Patterson, the distinction between hemp-derived and cannabis-derived THC is legally significant but pharmacologically irrelevant—both compounds activate the same cannabinoid receptors and produce comparable psychoactive effects. He emphasized that product safety depends on testing and quality control, not the source of the cannabinoid. Economic analyst Maria Chen, who tracks cannabis markets for Brightfield Group, said Virginia's restrictions will likely accelerate consumer migration to licensed dispensaries but may also drive some consumers to neighboring states or illicit markets. According to Chen's analysis, price sensitivity varies by consumer segment—medical users prioritize product consistency and are more likely to shift to licensed dispensaries, while recreational users seeking lower prices may explore alternatives including travel to North Carolina or West Virginia, where hemp laws differ. Virginia Hemp Coalition Executive Director Robert Chen said the restrictions eliminate a legal market that served consumers who preferred hemp products or lacked convenient access to licensed dispensaries. According to Chen, many rural Virginia residents live more than 50 miles from the nearest licensed dispensary but had local access to hemp retailers. He argued that the law reduces consumer choice and may increase reliance on unregulated sources. Public health researcher Dr. Linda Foster, who directs the Virginia Poison Center, said the restrictions address legitimate safety concerns about unregulated intoxicants. According to Foster, the Poison Center documented a 340% increase in calls related to hemp-derived cannabinoids between 2021 and 2024, with particular concern about accidental pediatric exposures to products that resembled candy. She noted that licensed cannabis products face packaging requirements including child-resistant containers and clear labeling, while hemp products often lacked such protections. Cannabis industry consultant David Torres, who advises multi-state operators, said Virginia's approach creates compliance challenges for national hemp brands but provides a clearer regulatory framework than the previous ambiguity. According to Torres, businesses prefer clear rules to regulatory uncertainty, even if those rules restrict market opportunities. He predicted that national hemp manufacturers would increasingly segment product lines by state, developing Virginia-compliant formulations alongside higher-potency products for less restrictive markets.

What's Next

Virginia's hemp market will continue evolving through late 2026 and into 2027 as businesses adapt, enforcement begins, and potential legal challenges develop. Immediate enforcement priorities for the Virginia Department of Agriculture and Consumer Services include compliance inspections at retail locations and product testing to verify THC content. The department announced plans to conduct random testing of hemp products beginning in September 2026, with initial focus on product categories most likely to exceed limits including vape cartridges, gummies, and flower. Retailers selling non-compliant products after August 15 face administrative penalties and potential license revocation. Potential legal challenges remain under consideration by hemp industry groups. The Virginia Hemp Coalition consulted with attorneys about possible claims that the state law conflicts with federal hemp law or imposes an undue burden on interstate commerce. However, legal experts generally assess such challenges as unlikely to succeed given the 2018 Farm Bill's explicit preservation of state regulatory authority. Any lawsuit would likely be filed in Virginia state court or the U.S. District Court for the Eastern District of Virginia. Market consolidation appears likely as smaller hemp retailers exit the cannabinoid market and larger operators with diversified product lines absorb market share. Industry analysts predict that 20% to 30% of Virginia hemp retailers focused primarily on intoxicating products may close by mid-2027, while retailers offering broader product ranges including non-intoxicating CBD, wellness products, and accessories will adapt more successfully. Product innovation may focus on compliant formulations emphasizing minor cannabinoids including CBG, CBN, and CBC, which lack significant intoxicating effects but offer potential therapeutic benefits. Some manufacturers are exploring combinations of low-dose THC within the 0.3% limit alongside other cannabinoids to create entourage effects. However, these products serve different consumer needs than the high-potency intoxicants they replace. Legislative monitoring will track whether the Virginia General Assembly makes technical corrections or adjustments to the law in the 2027 session. Potential amendments could address implementation issues, clarify testing protocols, or adjust enforcement penalties. Some industry advocates hope to negotiate amendments allowing higher per-serving limits for specific product categories, though such changes face opposition from public health advocates and the licensed cannabis industry. Regional policy developments in neighboring states will influence Virginia's market dynamics. North Carolina, West Virginia, and Tennessee maintain different hemp regulations, creating potential cross-border shopping opportunities. If neighboring states impose similar restrictions, regional market consolidation could accelerate. Conversely, if neighboring states maintain more permissive rules, Virginia may face pressure to revisit its approach to remain competitive. Federal regulatory developments could reshape the landscape. The U.S. Food and Drug Administration continues developing regulations for CBD and other hemp-derived cannabinoids in food and dietary supplements, though progress has been slow. The DEA could clarify its position on synthetically derived cannabinoids including delta-8 THC. Congressional legislation addressing hemp intoxicants has been proposed but not advanced, leaving states as the primary regulators. Long-term market evolution may see convergence between hemp and cannabis regulatory frameworks. Some policy analysts predict that states will increasingly regulate all intoxicating cannabinoids through unified systems, regardless of whether they derive from hemp or cannabis. This approach would eliminate the current regulatory bifurcation and create consistent standards for testing, labeling, taxation, and distribution.

Further Reading

• Agriculture Improvement Act of 2018 (2018 Farm Bill), Pub. L. 115-334 — https://www.congress.gov/bill/115th-congress/house-bill/2
• Virginia Code § 3.2-4112 et seq. (Hemp Regulation) — https://law.lis.virginia.gov/vacode/title3.2/chapter41.1/
• Virginia Code § 4.1-600 et seq. (Cannabis Control Act) — https://law.lis.virginia.gov/vacode/title4.1/chapter6/
• Virginia Department of Agriculture and Consumer Services Hemp Program — https://www.vdacs.virginia.gov/plant-industry-services-hemp.shtml
• Virginia Cannabis Control Authority — https://www.cannabis.virginia.gov/
• DEA Interim Final Rule on Hemp (August 2020) — https://www.federalregister.gov/documents/2020/08/21/2020-18484/implementation-of-the-agriculture-improvement-act-of-2018
• USDA Hemp Production Program — https://www.ams.usda.gov/rules-regulations/hemp
• Virginia Hemp Coalition — https://www.vahempcoalition.org/
• Virginia Cannabis Industry Association — https://www.vacannabis.org/
• Virginia Poison Center Data on Cannabinoid Exposures — https://www.vapoisoncenter.org/